Trial reportLipids1997
Increased dietary arachidonic acid enhances the synthesis of vasoactive eicosanoids in humans.
Trial report in Lipids, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 69 citations in OpenAlex.
- Vitamin B12 Status Upon Short-Term Intervention with a Vegan Diet-A Randomized Controlled Trial in Healthy Participants.Nutrients · 2019Trial
- Supplementation of arachidonic acid-enriched oil increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study.Lipids in health and disease · 2011Trial
- Trial
- A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design.Lipids · 1997Trial
- Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?British journal of pharmacology · 2017Review
- Positive Selection on a Regulatory Insertion-Deletion Polymorphism in FADS2 Influences Apparent Endogenous Synthesis of Arachidonic Acid.Molecular biology and evolution · 2016Article
- Plasma fatty acids, oxylipins, and risk of myocardial infarction: the Singapore Chinese Health Study.Journal of lipid research · 2016Article
- Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases.Current genomics · 2016Article
- Association between serum fatty acid composition and innate immune markers in healthy adults.Nutrition research and practice · 2016Article
- LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma.SpringerPlus · 2014Article
- Nutritional properties of dietary omega-3-enriched phospholipids.BioMed research international · 2013Review
- Association of plasma n-6 and n-3 polyunsaturated fatty acids with synovitis in the knee: the MOST study.Osteoarthritis and cartilage · 2012Article
- Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study.PloS one · 2012Article
- Nutrigenomics: a case for the common soil between cardiovascular disease and cancer.Genes & nutrition · 2008Article
- Disturbances in essential fatty acid metabolism in patients receiving long-term home parenteral nutrition.Digestive diseases and sciences · 2002Article
- Assessment of the arachidonic acid content in foods commonly consumed in the American diet.Lipids · 1998Article
- Effect of dietary arachidonic acid on metabolism of deuterated linoleic acid by adult male subjects.Lipids · 1998Article
- Article
- Article
- High levels of dietary arachidonic acid triglyceride exhibit no subchronic toxicity in rats.Lipids · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the effect of dietary arachidonic acid (AA) (20:4n-6) on the synthesis of thromboxane and prostacyclin (PGI2) in humans are lacking. We measured the effect of 1.5 g/d (ca. 0.5 en%) of 20:4n-6 added isocalorically to a stabilization (low-AA) diet on the excretion of 11-dehydrothromboxane B2 (11-DTXB2) and 2,3-dinor-6-oxo-PGF1 alpha (PGI2-M). In a crossover design, 10 healthy men, living in a metabolic unit, were fed a diet (low-AA) containing 210 mg/d of 20:4n-6 for 65 d and an identical diet (high-AA) that contained 1.5 g/d of additional 20:4n-6 for 50 d. Three-day urine pools were collected at the end of each dietary period and analyzed for eicosanoids by gas chromatography-electron capture negative ion-tandem mass spectrometry. Mean excretion of 11-dehydrothromboxane B2 was 515 +/- 76, 493 +/- 154, and 696 +/- 144 ng/d (SD; n = 10) during the acclimation (15 d) low-AA diet and high-AA diet periods, respectively (41% increase from low-AA to high-AA diet, P = 0.0037); mean excretion of PGI2-M was 125 +/- 40, 151 +/- 36, and 192 +/- 55 ng/d (SD; n = 10) during acclimation (15 d) low-AA and high-AA diets; P = 0.0143). Thus both the metabolites of thromboxane and PGI2 increase on the high-AA diet. Furthermore, both indicated changes in metabolite excretion may be associated with measurable effects on several physiologically significant cellular functions, such as platelet aggregation in vivo and inflammation in response to immune challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.